glp 1 or semaglutide Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity Wegovy® GLP-1 Semaglutide Injections -

The incidence of MACE was similar between LANTUS and standard care in ORIGIN (Hazard Ratio [95% CI] for MACE

These two small molecules, cAMP and Ca 2+ , are critical for incretin signaling

References Abdelaal M, le Roux CW, Docherty NG

Weight loss induced by these medications reduces visceral fat and hepatic triglyceride content, both associated with improved lipid profiles

However, it is critical to recognise that these direct mechanisms are considered secondary, and in some cases remain controversial, compared with the proven impact of indirect pathways

Clinical evidence does not show that GLP-1 agonists directly activate or worsen autoimmune thyroid disease